Global TB Progress Stalls As Gaps Persist
2026-08-11
A modest dip in tuberculosis cases is being oversold as success, while the disease still kills more people than any other infection. Reported incidence has edged downward, yet transmission chains remain entrenched across crowded cities, informal settlements and under-resourced clinics that lack basic microbiological testing.
The harder truth is that the WHO End TB strategy is stuck, not surging. Current spending on TB care and prevention falls far below the level health economists say is needed to scale molecular diagnostics such as nucleic acid amplification tests and to maintain consistent access to first-line and second-line drug regimens. Large numbers of infections go undetected, so incidence curves flatten instead of dropping sharply, and multidrug-resistant TB continues to emerge under weak treatment supervision and drug stockouts.
Global health agencies argue that TB is now a political failure more than a scientific one. Tools exist: interferon-gamma release assays for latent infection, shorter drug combinations for active disease, digital adherence technologies to track dosing. What is missing are reliable domestic and international budgets, protection for community health workers, and systems that can reach people who never enter formal care. The gap between what is technically possible and what is funded now defines the TB crisis.
Loading...
